Table 2. mRNA expression of 40 expressed druggable genes and CCND1, MKI67 in HNSCC relative to normal head and neck tissue and percentages of overexpressed tumors.
| Genes | Ct median of normal head and neck tissue (n= 27) | Normal head and neck tissue(n= 27) | HNSCC (n = 96) | % of overexpressed tumors (N target > 3) |
|---|---|---|---|---|
| PGF | 29.12 (27.97–30.25)a | 1.00 (0.37–2.26)b | 1.93 (0.57–15.5) | 30.2% |
| PDL1 | 28.60 (26.35–32.59) | 1.00 (0.12–2.95) | 1.67 (0.06–23.40) | 28.1% |
| CDK6 | 25.29 (23.88–27.41) | 1.00 (0.32–1.62) | 2.25 (0.33–8.32) | 20.8% |
| MET | 27.28 (25.33–28.42) | 1.00 (0.30–1.91) | 1.87 (0.21–16.5) | 17.7% |
| EGFR | 26.00 (24.08–27.31) | 1.00 (040–2.12) | 1.51 (0.21–46.1) | 13.5% |
| VEGFA | 25.70 (23.64–28.17) | 1.00 (0.34–2.32) | 1.43 (0.19–10.25) | 13.5% |
| IGF1R | 27.97 (26.07–30.90) | 1.00 (0.29–2.50) | 1.36 (0.18–4.62) | 8.3% |
| RET | 29.86 (26.86–32.75) | 1.00 (0.16–2.90) | 0.57 (0.05–26.5) | 7.3% |
| CDK4 | 24.95 (24.11–26.67) | 1.00 (0.67–1.38) | 1.39 (0.76–4.19) | 7.3% |
| KITLG | 27.76 (21.04–29.91) | 0.96 (0.34–2.55) | 0.85 (0.09–3.99) | 4.2% |
| PDGFRB | 25.23 (23.38–26.21) | 1.00 (0.21–1.89) | 1.02 (0.13–4.60) | 3.1% |
| PIK3CA | 25.92 (25.19–27.51) | 1.00 (0.67–1.76) | 1.14 (0.52–5.24) | 3.1% |
| FGFR1 | 24.84 (23.62–26.29) | 1.00 (0.25–1.84) | 0.37 (0.08–4.48) | 2.1% |
| FGFR3 | 25.23 (22.55–32.47) | 1.00 (0.01–2.95) | 0.73 (0.03–4.38) | 2.1% |
| IGF2 | 24.46 (22.23–26.06) | 1.00 (0.15–2.91) | 0.32 (0.00–3.90) | 2.1% |
| SRC | 26.69 (24.87–30.29) | 1.00 (0.12–2.11) | 1.39 (0.68–3.23) | 2.1% |
| VEGFR3 | 28.51 (26.93–29.74) | 1.00 (0.48–2.35) | 0.61 (0.14–3.52) | 2.1% |
| SMO | 27.75 (26.01–30.00) | 1.00 (0.34–2.45) | 0.65 (0.06–4.77) | 2.1% |
| DLL4 | 27.87 (26.26–29.83) | 1.00 (0.33–2.76) | 0.98 (0.38–3.63) | 2.1% |
| ERBB2 | 25.75 (23.78–29.99) | 1.00 (0.10–2.36) | 0.42 (0.08–3.56) | 1.0% |
| FGFR2 | 25.76 (23.33–33.59) | 1.00 (0.00–2.11) | 0.45 (0.07–4.06) | 1.0% |
| KIT | 28.19 (25.45–30.88) | 1.00 (0.21–2.80) | 0.26 (0.05–3.44) | 1.0% |
| ERBB3 | 25.96 (23.59–31.12) | 1.00 (0.05–2.86) | 0.48 (0.08–1.54) | 0.0% |
| ERBB4 | 29.95 (26.09–34.76) | 1.00 (0.03–2.97) | 0.03 (0.00–1.99) | 0.0% |
| HGF | 29.70 (27.66–31.12) | 1.00 (0.26–2.91) | 0.33 (0.05–2.24) | 0.0% |
| CSF1R | 25.97 (24.54–27.46) | 1.00 (0.47–2.38) | 0.76 (0.00–2.70) | 0.0% |
| PDGFRA | 25.27 (24.13–25.94) | 1.00 (0.35–1.99) | 0.47 (0.07–2.40) | 0.0% |
| DDR2 | 26.76 (24.66–27.60) | 1.00 (0.29–2.70) | 0.52 (0.07–1.75) | 0.0% |
| VEGFR1 | 26.04 (24.26–27.96) | 1.00 (0.30–2.82) | 0.88 (0.25–2.68) | 0.0% |
| VEGFR2 | 27.26 (25.74–28.42) | 1.00 (0.35–1.65) | 0.46 (0.12–1.78) | 0.0% |
| VEGFB | 26.33 (24.53–30.32) | 1.00 (0.16–2.52) | 0.63 (0.09–1.74) | 0.0% |
| STAT3 | 23.32 (22.00–24.61) | 1.00 (0.57–2.27) | 0.84 (0.24–1.64) | 0.0% |
| MDM2 | 24.71 (22.75–26.12) | 1.00 (0.39–1.73) | 0.86 (0.27–2.83) | 0.0% |
| ABL1 | 25.22 (24.22–26.48) | 1.00 (0.52–2.95) | 0.69 (0.20–2.03) | 0.0% |
| NOTCH1 | 27.82 (25.93–29.22) | 1.00 (0.36–2.03) | 0.71 (0.12–2.23) | 0.0% |
| NOTCH2 | 26.13 (25.14–27.75) | 1.00 (0.47–2.15) | 0.72 (0.16–1.67) | 0.0% |
| NOTCH4 | 27.72 (26.51–29.10) | 1.00 (0.42–2.95) | 0.65 (0.07–2.40) | 0.0% |
| JAK2 | 25.75 (24.28–26.87) | 1.00 (0.41–2.58) | 0.48 (0.07–2.51) | 0.0% |
| TEK | 27.20 (25.85–28.30) | 1.00 (0.24–2.49) | 0.29 (0.07–1.42) | 0.0% |
| AKT1 | 24.72 (23.64–26.40) | 1.00 (0.66–1.61) | 1.12 (0.49–2.15) | 0.0% |
| CCND1 | 23.87 (21.70–27.36) | 1.00 (0.14–2.91) | 1.44 (0.19–13.85) | 27.0% |
| MKI67 | 27.36 (25.13–35.33) | 1.00 (0.00–1.58) | 2.39 (0.61–13.37) | 31.3% |
a
Median (range) of gene Ct (Cycle threshold) values.
b
Median (range) of gene mRNA levels. The mRNA values of the samples were normalized such that the median of the 27 normal head and neck mRNA values was 1.